Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
US9512107 | CELGENE CORP | Therapeutically active compositions and their methods of use |
Jan, 2033
(9 years from now) | |
US9738625 | CELGENE CORP | Therapeutically active compounds and their methods of use |
Aug, 2034
(11 years from now) | |
US10093654 | CELGENE CORP | Therapeutically active compounds and their methods of use |
Aug, 2034
(11 years from now) | |
US9732062 | CELGENE CORP | Therapeutically active compounds and their methods of use |
Sep, 2034
(11 years from now) | |
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US10610125 | CELGENE CORP | Methods and compositions for cell-proliferation-related disorders |
Jun, 2030
(7 years from now) | |
US10294215 | CELGENE CORP | Therapeutically active compounds and their methods of use |
Jan, 2033
(9 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
Orphan Drug Exclusivity (ODE) | Aug 1, 2024 |
New Chemical Entity Exclusivity (NCE) | Aug 1, 2022 |
Drugs and Companies using ENASIDENIB MESYLATE ingredient
NCE-1 date: August, 2021
Market Authorisation Date: 01 August, 2017
Treatment: Treatment of relapsed or refractory acute myeloid leukemia (aml) with an isocitrate dehydrogenase-2 (idh2) mutation
Dosage: TABLET;ORAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8846628 | CELGENE CORP | Oral formulations of cytidine analogs and methods of use thereof |
Jun, 2030
(7 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
New Product (NP) | Sep 1, 2023 |
Orphan Drug Exclusivity (ODE) | Sep 1, 2027 |
Drugs and Companies using AZACITIDINE ingredient
Market Authorisation Date: 01 September, 2020
Treatment: Continued treatment of adults with acute myeloid leukemia who achieved first complete remission (cr) or cr with incomplete blood count recovery following intensive induction chemotherapy and are not able to complete intensive curative therapy
Dosage: TABLET;ORAL
Click on the highlighted region to filter.
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic